NR2F1-AS1 (NR2F1 Antisense RNA 1)

These features allowed the model to robustly distinguish cold from hot tumor phenotypes. Necroptosis-related lncRNAs, particularly NR2F1-AS1, may serve as prognostic biomarkers and inform immune-based stratification, supporting more precise personalized treatment strategies for PCa.

Notably, its biological function appears to be context-dependent: acting as an oncogene in many cancer types, such as breast, lung, liver, and gastric cancer, while exhibiting potential tumor-suppressive activity in others, including colorectal cancer, cervical squamous cell carcinoma, and thymic epithelial tumors. This review comprehensively summarizes the aberrant expression patterns, prognostic significance, biological functions, and molecular mechanisms of NR2F1-AS1, while also highlighting its emerging potential as a context-specific diagnostic biomarker and therapeutic target in human cancers.

In prostate cancer, we utilized high-plasticity mouse models and enzalutamide-resistant (ENZ-R) cellular models to elucidate NR2F1 as a key factor in lineage transition and ENZ resistance...Furthermore, HnRNPA2B1 interacts with NR2F1 and NR2F1-AS1, assisting their packaging into exosomes, wherein exosomal NR2F1 and NR2F1-AS1 promote the proliferation of dormant ENZ-R cells. Our works offer novel insights into the reawaking of dormant drug-resistant cancer cells governed by NR2F1 upregulation triggered by exosome-derived NR2F1-AS1 and NR2F1, suggesting therapeutic potential for phenotype reversal.

The RNF217-AS1 ORF-encoded peptide in human SC AGS cells suppressed THP-1 cell migration, triggered the differential expression of CXCL1/CXCL2/CXCL8/CXCL12, and inactivated the TLR4/NF-κB/STAT1 signaling pathways. As a conclusion, the RNF217-AS1 ORF-encoded peptide hindered SC progression in vitro and in vivo and suppressed macrophage recruitment and pro-inflammatory responses in SC.

However, the difference in age (OR = 1.10,95%Cl 0.71-1.71, p = 0.34), gender (OR = 1.26,95%Cl 0.79-2.00, p = 0.34), Lymph node metastasis (OR = 1.44,95%Cl 0.27-7.80, p = 0.67) or larger tumor size (OR = 1.56,95%Cl 0.48-5.08, p = 0.46) was not statistically significant. Upregulation of LncRNA NR2F1-AS1 was associated with poor prognosis and advanced clinicopathologic features of tumor patients.

The novel predictive pattern allows for efficient categorization of patients with bladder cancer, enabling focused and rigorous treatment for those expected to have a worse prognosis. The discovery of a possible curative medication establishes a basis for forthcoming immunotherapy trials in bladder cancer.

Mechanistically, lnc NR2F1-AS1 competitively binds to miR-25-3p to impede ZEB2 degradation, a positive EMT transcription factor in BC. Our study revealed a novel lnc NR2F1-AS1/miR-25-3p/ZEB2 axis in BC metastasis and that lnc NR2F1-AS1 may serve as a potential therapeutic target for BC metastasis.

NR2F1-AS1 is a potential new biomarker and therapeutic target for the treatment of different cancers.